Insys Therapeutics' fentanyl-bribery scheme

It started with a drug that was meant for a very specific group of patients , people suffering from cancer.

Then federal investigators began looking into how widely it was actually being prescribed.

According to prosecutors, Insys Therapeutics executives were involved in a scheme to increase prescriptions of a powerful fentanyl spray by allegedly bribing doctors and using fraudulent methods. The company’s founder and CEO, John Kapoor, was accused of leading the operation, with investigators claiming that the drug was being pushed onto patients who didn’t necessarily need it.

The allegations eventually led to Kapoor’s arrest following a federal investigation, bringing the company’s prescribing practices into the spotlight.

The disturbing part wasn’t simply the drug itself , it was the suggestion that something designed for patients with severe medical needs could allegedly be turned into a much broader source of profit.

The claims described here come from federal investigators and charges surrounding the case, rather than being presented as established fact by the original source.

Source, public reporting on the federal case involving Insys Therapeutics.